Overview

Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy

Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
A Phase 2, double-blind, placebo-controlled study will evaluate the efficacy and safety of tomivosertib in subjects with NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Effector Therapeutics
Collaborator:
Medpace, Inc.
Treatments:
Pembrolizumab